Day One Biopharmaceuticals (DAWN) FY Conference June 10, 2025 08:40 AM ET Speaker0 Good morning, everyone. Thanks so much for joining us. I'm Andrea Newkirk, one of the biotech analysts here at Goldman Sachs, and I'm really pleased to be joined by Jeremy Bender, COO and CFO of Dawn. Thank you guys both for joining us. Speaker1 Andrea, thanks for having us. It's great to be here. Speaker0 Great. Well, as we sit here today, Ogemda has been on the market now for over a year. What has been the biggest learnings ...

Day One Biopharmaceuticals (DAWN) 2025 Conference May 13, 2025 11:00 AM ET Speaker0 Equity Capital. So sitting in a really strong financial position as well. To get to your point specifically, I'll I'll touch on some highlights and then pass it over to Lauren, our chief commercial officer to dig into a little bit of the details. But at a very high level, we're very pleased with where we are right now in regards to the commercial launch of it. It's been about $90,000,000 of revenue in the first eleven months ...

Day One Biopharmaceuticals (DAWN) Q1 2025 Earnings Call May 06, 2025 04:30 PM ET Company Participants Joey Perrone - SVP - Investor RelationsJeremy Bender - CEO, President & DirectorLauren Merendino - Chief Commercial OfficerCharles York - COO, CFO & SecretaryAlec Stranahan - Vice President - Equity ResearchElly Barry - Chief Medical OfficerAndrea Newkirk - Biotechnolgy Equity ResearchAndres Maldonado - Vice President Conference Call Participants None - AnalystTara Bancroft - Director, Senior Analyst, Biote ...

Day One Biopharmaceuticals (DAWN) Q1 2025 Earnings Call May 06, 2025 04:30 PM ET Speaker0 Hello, ladies and gentlemen, and welcome to the DayOne Biopharmaceuticals First Quarter twenty twenty five Financial and Operating Results Conference Call. At this time, all participants are in a listen only mode. Later, we will conduct a question and answer session. Please be advised that this conference call is being recorded. I would now like to turn the call over to Joy Peroni, Senior Vice President of Finance and ...